Latest news with #PeterAndersen
Al Etihad
3 days ago
- Business
- Al Etihad
Wall Street slips after Trump's steel tariff threat
2 June 2025 19:04 NEW YORK (REUTERS)Wall Street's main indexes dipped on Monday after President Donald Trump said he plans to double tariffs on imported steel and aluminum, fueling more uncertainty around U.S. trade said late on Friday he planned to increase tariffs on imported steel and aluminum to 50% from 25% starting Wednesday, just hours after he accused China of violating an of U.S. steel companies rose, with Cleveland-Cliffs jumping 28.3%, Nucor up 11.5% and Steel Dynamics 11.3% shares of automakers fell. Ford and General Motors both were down more than 4%."People have been thinking about that (steel tariffs) and trying to formulate the economic impact. It presents the markets with a lot of uncertainty right now," said Peter Andersen, founder at Andersen Capital increased levies risk deepening Trump's global trade war, and dousing enthusiasm in markets stemming from the U.S. president's softer trade stance that drove a recovery in risky assets last month.A temporary relief on some levies on China and a rollback of steep tariff threats on the European Union, along with strong earnings and improving economic picture helped the benchmark S&P 500 log its best monthly performance in 18 months in fueling risk-off moves in global markets, Kyiv struck some of Moscow's nuclear-capable bombers on Sunday, renewing concerns around further escalation of the 10:31 a.m. ET, the Dow Jones Industrial Average fell 208.46 points, or 0.49%, to 42,061.61, the S&P 500 lost 15.78 points, or 0.27%, to 5,895.91 and the Nasdaq Composite lost 10.10 points, or 0.05%, to 19, of the 11 major S&P 500 sub-sectors fell, with consumer discretionary stocks declining the most with an about 1% fall. On the flip side, energy rose 0.8% tracking a rise in oil prices.U.S.-listed energy stocks advanced after producer group OPEC+ kept output increases in July at the same level as the previous two megacap and growth stocks were down, with Tesla leading losses with a 2.5% decline after it reported lower monthly sales for Portugal, Denmark and the economic front, the Institute for Supply Management's (ISM) gauge of manufacturing activity came in at 48.5 for May, below estimates of 49.3, according to economists polled by will be on comments from Federal Reserve Chair Jerome Powell later in the day as he presents opening remarks before the Federal Reserve Board International Finance Division's 75th anniversary conference at 1:00 p.m. ET (1700 GMT).Investors are also looking ahead to a crucial nonfarm-payrolls report on Friday to gauge the U.S. labour market's strength amid tariff issues outnumbered advancers by a 1.84-to-1 ratio on the NYSE and by a 1.43-to-1 ratio on the Nasdaq. The S&P 500 posted 10 new 52-week highs and four new lows, while the Nasdaq Composite recorded 51 new highs and 63 new lows. Stock Markets Continue full coverage
Business Wire
13-05-2025
- Health
- Business Wire
TreeFrog Therapeutics Presents Delivery Strategy for Next Generation 3D Cell Therapy Format for Parkinson's Disease at the 28th Annual ASGCT Meeting in New Orleans
BORDEAUX, France--(BUSINESS WIRE)--TreeFrog Therapeutics, a French biotech specializing in cell therapy is the first company to present a clinical-ready delivery strategy for 3D microtissues cell therapy. The validated approach was demonstrated for their 3D neural microtissues cell therapy treatment for Parkinson's disease. "I am excited to present a validated strategy for 3D format cell therapy for Parkinson's disease which took 4 years of development and overcomes challenges to ensure homogenization and accurate dose delivery." Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease. It is a progressive disease characterized by the loss of dopaminergic neurons with a mix of motor symptoms (bradykinesia, rigidity, resting tremor) and non-motor symptoms (cognitive deficits, mood disorders, fatigue). Current treatments provide symptomatic relief only. There is a huge unmet need with a prevalence that has doubled in the last 25 years to an estimated 10 million sufferers, and it is expected to double again by 2050 1, 2. Research into cell replacement strategies for Parkinson's disease has been ongoing for decades and the promise of cell therapy in the disease has resulted in a dynamic clinical trial landscape. Since 2021, when there were 5 trials in Parkinson's disease, there have been 15 new trials initiated or planned 3. Most cell therapies rely on single-cell suspensions which, while still holding promise, face specific challenges such as elevated cell death due to anoikis. Next generation 3D formats such as the neural microtissues in development by TreeFrog have emerged as a potential solution as the microtissue is in itself a network, providing protection to the cells and facilitating transplantation. Peter Andersen, Chief R&D Officer, TreeFrog Therapeutics commented 'I am excited to present, for the first time, a validated delivery strategy for a 3D microtissue format cell therapy. The development took 4 years, and I am proud of what the cross-functional team has achieved. 3D formats have huge potential, but the team also had to overcome challenges such as faster sedimentation to ensure homogenization and accurate dose delivery. The team also focused on developing a device using existing components which will facilitate education of use for neurosurgeons and their teams.' To learn more about this delivery strategy, those attending the ASGCT can attend the poster session and exchange with Peter Andersen: Venue: On-site Poster Hall Title: Development of a Delivery Strategy for Neural Microtissues in Parkinson's Disease Cell Therapy (#2039) Link to Late-Breaking Abstracts ASGCT Abstracts About TreeFrog Therapeutics TreeFrog Therapeutics is a French-based regenerative medicine biotech set to unlock access to cell therapies for millions of patients with a lead program in Parkinson's disease. TreeFrog is unique in its approach to cell therapy development, bringing together biophysicists, cell biologists and bioproduction engineers to address the challenges of the industry - producing and differentiating cells of quality at unprecedented scale, cost-effectively. To succeed in their mission of Cell Therapy for all, TreeFrog operates a business model that includes its own therapeutic programs and partnerships with leading biotech and industry players. Since 2021, the company has raised $82 million to advance a pipeline of stem cell-based therapies in regenerative medicine. 1 2 Su D et al. Projections for prevalence of Parkinson's disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ. 2025;388:e080952 3
